Total Funding
43
Total FundingPost-IPO Equity raised
Growth Score
pts
Heat Score
-17 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
238139
OHR Pharmaceutical develops products for the treatment of cancer cachexia and wet age-related macular degeneration.
Acquired by 
NeuBase Therapeutics
- Irach Taraporewala: FounderPast Role: OHR Pharmaceutical, President, CEO & Director
About the Company
OHR Pharmaceutical is a development-stage biotechnology company that focuses on the development of products for the treatment of cancer cachexia (multi-symptom wasting disorder) and wet- age-related macular degeneration.
It was founded in 2009 and is headquartered in New York, New York.
